SANTA MONICA, Calif., Dec. 4 /PRNewswire-FirstCall/ -- Aida Pharmaceuticals (OTC:AIDA) (BULLETIN BOARD: AIDA) today announced that the company's upcoming Rh-Apo2L cancer drug has been named as a "New and High-Tech Transforming Products of 2007" by the Shanghai New High Technology Service Centre ("SNHTSC"), a special government commercialization division led by the Shanghai Municipal Government. This designation will allow Rh-Apo2L to have preferential policies during the commercialization process after Aida completes China's State Food and Drug Administration ("SFDA") clinical testing of the product. The stated role of the SNHTSC, according to its website http://www.hitec.net.cn/, is to be a clearinghouse that allows the Chinese government to evaluate and narrow down technology candidates that have the greatest potential for national and global commercialization. Candidates must go through a strict appraisal by SNHTSC's expert committee, comprised of ten experts and government officials from differing fields of study. About Aida Pharmaceuticals Aida Pharmaceuticals is a product-focused pharmaceuticals company engaged in the formulation, clinical testing, registration, manufacture, sales and marketing of advanced pharmaceutical and genetic products in mainland China. The Company's mission is to discover, develop and market meaningful new therapies that improve human health. Aida Pharmaceuticals, in operation since March 1999, is headquartered in Hangzhou, China with manufacturing, distribution and sales points throughout mainland China. Aida is GMP certified in China and ISO9002 certified for quality assurance and ISO14000 certified for ecologically-friendly practices. SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995 With the exception of historical information, the matters discussed in this news release are forward-looking statements that involve a number of risks and uncertainties. The actual future results of Aida Pharmaceuticals could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the company's operations, inability to hire and retain qualified personnel, and changes in the general economic climate. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of such terms, or other comparable terminology. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by Aida Pharmaceuticals, or any other person, that such forward-looking statements will be achieved. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements. DATASOURCE: Aida Pharmaceuticals CONTACT: Ashley Hull, +1-310-450-9100, , for Aida Pharmaceuticals

Copyright